Celldex Therapeutics, Inc. (CLDX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Celldex announced Q1 2026 financial results on May 7, 2026, triggering disclosure requirements under Item 2.02 of Form 8-K for results of operations and financial condition.
The press release is furnished as an exhibit but explicitly not filed under Section 18 of the Exchange Act, limiting liability exposure for forward-looking statements and other disclosures.
The filing was signed by Sam Martin, Senior Vice President and Chief Financial Officer, indicating proper authorization and corporate governance procedures were followed.
As a Nasdaq Capital Market-listed company, Celldex maintains standard SEC reporting obligations but does not qualify as an emerging growth company with extended transition periods.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-02

Celldex Therapeutics is raising $282 million through a public offering of 10.3 million shares at $29 per share, which could provide additional funding for the company's drug development pipeline.
The underwriters have a 30-day option to purchase up to an additional 1.6 million shares, which could increase the total capital raised.
The timing of the offering, shortly after Celldex's annual 10-K filing, suggests the company may be looking to fund new initiatives or accelerate ongoing research and development programs.

Filed: 2026-02-25

Celldex Therapeutics reported its Q4 2025 and full-year 2025 financial results, which appear to be in line with expectations.
The company did not provide any material updates or new developments in its press release, suggesting an absence of significant news for investors.
With no major catalysts or surprises, this 8-K filing seems to be a routine quarterly earnings report without major implications for Celldex's outlook.

Other reports for Celldex Therapeutics, Inc.

Quarterly Report Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.